Vaginitis Diagnostics Market

Vaginitis Diagnostics Market (Testing Type: Nucleic Acid Amplification Assays, DNA Probe, and Clinical Test; Disease Type: Bacterial Vaginosis/Vaginitis, Vulvovaginal Candidiasis, Trichomoniasis, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Vaginitis Diagnostics Market Outlook 2031

  • The global vaginitis diagnostics market was valued at US$ 1.7 Bn in 2021
  • The global market is projected to advance at a CAGR of 9.5% from 2022 to 2031
  • The global vaginitis diagnostics market is anticipated to reach more than US$ 4.1 Bn by 2031

Analysts’ Viewpoint on Vaginitis Diagnostics Market Scenario

Screening and detection of bacterial, yeast, fungi, and viral samples in clinical pathology using microscopy and vaginal testing panels have led to less turnaround time. This is ascribed to lower chances of producing false positive results using these panels because of their broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of results. The number of diagnostic vaginal testing procedures is likely to increase as more women undergoing vaginal test are likely to benefit from this advancement, which in turn is expected to propel the global market during the forecast period. Incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, high specificity of the nucleic acid amplification test presents significant opportunities for leading players in the global market.

Vaginitis Diagnostics Market

Vaginitis Diagnostics Market Introduction

Vaginitis is defined as any condition with symptoms of abnormal vaginal discharge, odor, and irritation, itching, or burning. Bacterial vaginosis is the most common cause of vaginal symptoms among women. According to the CDC, in 2021, prevalence of vaginitis in the U.S. is estimated to be 21.2 million (29.2%) among women aged 14 to 49. Vaginitis diagnostic test is used for the detection of diseases such as bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginosis. Vaginosis diagnosis and vulvovaginal candidiasis vaginitis diagnosis (VVC diagnosis) are performed using a combination of clinical signs and symptoms with potassium hydroxide microscopy culture that can be helpful for the diagnosis of bacterial vaginitis. Real-time polymerase chain reaction (PCR) and amplification of specific DNA targets are the technologically advanced tests available in the global market for the purpose of fast vaginosis diagnosis.

COVID-19 Impact on Vaginitis Diagnostics Market

The COVID-19 pandemic had a negative effect on the global vaginitis diagnostics market. Governments of affected countries postponed non-essential treatment and patient visits during the breakout year of COVID-19. Hospital personnel and medical staff were moved to COVID-19 cases, prompting the suspension of outpatient visits for sexual diseases. This led to a substantial decline in overall vaginosis diagnosis and VVC diagnosis & treatments, which in turn hampered the vaginitis diagnostic market. Key players reported lower revenue due to the pandemic, which led to a decline in Y-o-Y global vaginitis diagnostics market share. However, the market has recovered from COVID-19 due to the easing of restrictions by governments across the globe.

Increase in Usage for Diagnosis & Screening of Vaginal Infections Driving Nucleic Acid Amplification Test (NAAT) Segment

In terms of testing type, the nucleic acid amplification test segment held major market share in 2021. Increase in the usage of molecular nucleic acid amplification tests for vaginosis diagnosis & VVC diagnosis and screening of vaginal infections due to high accuracy and sensitivity in the production of results is anticipated to propel the segment in the near future. Nucleic acid amplification tests (NAATs), such as PCR, can identify as little as one organism in a sample. These employ techniques that multiply a nucleic acid sequence enzymatically, resulting in the synthesis of billions of copies in a short time.

High Prevalence in Women of Reproductive Age Bolstering Bacterial Vaginosis Segment

Based on disease type, the bacterial vaginosis/vaginitis segment dominated the global market in 2021. Bacterial vaginosis (BV) is the most prevalent cause of vaginal discharge in women of reproductive age. It is not a sexually transmitted disease; however, sexual activity is a risk factor for its transmission. It is linked to changes in vaginal ecology, including a reduction in the vaginal lactobacilli population and an overgrowth of anaerobes and G. vaginalis. Bacterial vaginosis is the more prevalent vaginal microbiota among women of reproductive age. This has increased the demand for bacterial vaginosis diagnosis. For instance, the prevalence of bacterial vaginosis in North America stands at around 20% to 30%.

Rise in Emphasis on Early Diagnostics of Vaginal Infections Fueling Hospitals Segment

In terms of end-user, the hospitals segment accounted for major share of the global market in 2021. Increase in focus on providing quality care, rise in emphasis on early diagnostics of vaginal infections, and surge in the number of well-equipped specialty hospitals are expected to augment the hospitals segment during the forecast period. Growth of the segment can be ascribed to rise in prevalence of infectious diseases such as vaginal infections and increase in awareness about these infections among people.

Regional Outlook of Global Vaginitis Diagnostics Market

North America accounted for the largest share of the global market in 2021. The region is projected to be a highly attractive market during the forecast period. Increase in health awareness, rise in investment in healthcare infrastructure, and surge in demand for better healthcare facilities propel the vaginitis diagnostics market in North America. The U.S. dominated the market in North America in 2021. The trend is anticipated to continue during the forecast period due to large number of patients and favorable reimbursement for vaginitis. Europe was the second-largest market for vaginitis diagnostics in 2021. Favorable regulatory scenario, approval of products, and presence of highly developed infrastructure are likely to augment the vaginitis diagnostics market size in the region in the next few years.

As per global vaginitis diagnostics market forecast, the market in Asia Pacific is projected to grow at a rapid pace during the forecast period owing to increase in the geriatric population in countries such as Japan and China, higher incidence rate of vaginitis, rise in per capita income, and improved healthcare infrastructure. Moreover, increase in healthcare expenditure and investments by key players in emerging economies is expected to propel the market in the region.

Analysis of Key Players in Global Vaginitis Diagnostics Market

The vaginitis diagnostics market report includes vital information about the key players operating in the global market. Companies focus on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Cepheid (Danaher Corporation), Abbott Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Hologic, Quidel Corporation, Quest Diagnostics Incorporated, Atrida, and Becton, Dickinson and Company are the prominent players operating in the global market.

Key Developments in Global Vaginitis Diagnostics Market

  • In October 2021, Hologic announced the European launch of the Novodiag system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021. It will bring the benefits of the Novodiag system to a broader range of customers in the region.
  • On August 25, 2021, Becton, Dickinson and Company announced the launch of a new, fully automated high-throughput diagnostic system using robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the U.S.
  • In September 2020, Danaher Corporation entered into a definitive merger agreement with Cepheid, pursuant to which, Danaher would acquire all of the outstanding shares of Cepheid for US$ 53.00 per share in cash, or a total enterprise value of around US$ 4 Bn. Cepheid is a leading global molecular diagnostics company that develops, manufactures, and markets accurate and easy to use molecular systems and tests.
  • In January 2018, Roche launched cobas TV/MG on the cobas 6800/8800 Systems in markets accepting the CE mark. cobas 6800/8800 Systems is used for the direct detection of Trichomonas vaginalis (TV) and/or Mycoplasma genitalium (MG) DNA in both symptomatic and asymptomatic individuals.

Key players have been profiled in the vaginitis diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Vaginitis Diagnostics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.7 Bn

Market Forecast Value in 2031

More than US$ 4.1 Bn

Compound Annual Growth Rate (CAGR)

9.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Testing Type
    • Nucleic Acid Amplification Assays
    • DNA Probe
    • Clinical Test
  • Disease Type
    • Bacterial Vaginosis/Vaginitis
    • Vulvovaginal Candidiasis
    • Trichomoniasis
    • Others
  • End-user
    • Hospitals
    • Specialty Clinics
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott Laboratories
  • Atrida
  • Becton, Dickinson and Company
  • Cepheid (Danaher Corporation)
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • QIAGEN
  • Quest Diagnostics Incorporated
  • Quidel Corporation

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global vaginitis diagnostics market in 2021?

The global vaginitis diagnostics market was valued at US$ 1.7 Bn in 2021.

How big will be the global vaginitis diagnostics market by 2031?

The global vaginitis diagnostics market is projected to reach more than US$ 4.1 Bn by 2031.

What will be the CAGR of the global vaginitis diagnostics market during the forecast period (2022–2031)?

The global vaginitis diagnostics market is anticipated to advance at a CAGR of 9.5% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in the incidence & prevalence of vaginal infection and rise in research & development on novel techniques.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global vaginitis diagnostics market during the forecast period.

Who are the prominent players in the global vaginitis diagnostics market?

Laboratory Corporation of America Holdings, Cepheid (Danaher Corporation), Abbott Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Hologic, Quidel Corporation, Quest Diagnostics Incorporated, Atrida, and Becton, Dickinson and Company.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Vaginitis Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Testing Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Vaginitis Diagnostics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Key Industry Events (New Product Launches/Key Mergers & Acquisitions)

        5.2. Technological Advancements

        5.3. Disease Incidence and Prevalence

        5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/ Long-Term Impact)

    6. Global Vaginitis Diagnostics Market Analysis and Forecast, by Testing Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Testing Type, 2017–2031

            6.3.1. Nucleic Acid Amplification Assays

            6.3.2. DNA Probe

            6.3.3. Clinical Test

        6.4. Market Attractiveness Analysis, by Testing Type

    7. Global Vaginitis Diagnostics Market Analysis and Forecast, by Disease Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Disease Type, 2017–2031

            7.3.1. Bacterial Vaginosis/Vaginitis

            7.3.2. Vulvovaginal Candidiasis

            7.3.3. Trichomoniasis

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Disease Type

    8. Global Vaginitis Diagnostics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Specialty Clinics

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Vaginitis Diagnostics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Vaginitis Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Testing Type, 2017–2031

            10.2.1. Nucleic Acid Amplification Assays

            10.2.2. DNA Probe

            10.2.3. Clinical Test

        10.3. Market Value Forecast, by Disease Type, 2017–2031

            10.3.1. Bacterial Vaginosis/Vaginitis

            10.3.2. Vulvovaginal Candidiasis

            10.3.3. Trichomoniasis

            10.3.4. Others

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Specialty Clinics

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Testing Type

            10.6.2. By Disease Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Vaginitis Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Testing Type, 2017–2031

            11.2.1. Nucleic Acid Amplification Assays

            11.2.2. DNA Probe

            11.2.3. Clinical Test

        11.3. Market Value Forecast, by Disease Type, 2017–2031

            11.3.1. Bacterial Vaginosis/Vaginitis

            11.3.2. Vulvovaginal Candidiasis

            11.3.3. Trichomoniasis

            11.3.4. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Specialty Clinics

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Testing Type

            11.6.2. By Disease Type

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Vaginitis Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Testing Type, 2017–2031

            12.2.1. Nucleic Acid Amplification Assays

            12.2.2. DNA Probe

            12.2.3. Clinical Test

        12.3. Market Value Forecast, by Disease Type, 2017–2031

            12.3.1. Bacterial Vaginosis/Vaginitis

            12.3.2. Vulvovaginal Candidiasis

            12.3.3. Trichomoniasis

            12.3.4. Others

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals

            12.4.2. Specialty Clinics

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Testing Type

            12.6.2. By Disease Type

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Vaginitis Diagnostics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Testing Type, 2017–2031

            13.2.1. Nucleic Acid Amplification Assays

            13.2.2. DNA Probe

            13.2.3. Clinical Test

        13.3. Market Value Forecast, by Disease Type, 2017–2031

            13.3.1. Bacterial Vaginosis/Vaginitis

            13.3.2. Vulvovaginal Candidiasis

            13.3.3. Trichomoniasis

            13.3.4. Others

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals

            13.4.2. Specialty Clinics

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Testing Type

            13.6.2. By Disease Type

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Vaginitis Diagnostics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Testing Type, 2017–2031

            14.2.1. Nucleic Acid Amplification Assays

            14.2.2. DNA Probe

            14.2.3. Clinical Test

        14.3. Market Value Forecast, by Disease Type, 2017–2031

            14.3.1. Bacterial Vaginosis/Vaginitis

            14.3.2. Vulvovaginal Candidiasis

            14.3.3. Trichomoniasis

            14.3.4. Others

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals

            14.4.2. Specialty Clinics

            14.4.3. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Testing Type

            14.6.2. By Disease Type

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Laboratory Corporation of America Holdings

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Company Financial

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Cepheid (Danaher Corporation)

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Company Financial

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Abbott Laboratories

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Company Financial

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. QIAGEN

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Company Financial

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. F. Hoffmann-La Roche Ltd.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Company Financial

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Hologic, Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Company Financial

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Quidel Corporation

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Company Financial

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Quest Diagnostics Incorporated

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Company Financial

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Atrida

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Strategic Overview

            15.3.10. Becton, Dickinson and Company

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Company Financial

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Vaginitis Diagnostics Market Value Share, by Testing Type, 2021

    Table 02: Global Vaginitis Diagnostics Market Value Share, by Disease Type & End-user, 2021

    Table 03: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 04: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 05: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 06: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Region, 2018–2031

    Table 07: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 08: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 09: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 10: North America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country, 2018–2031

    Table 11: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 12: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 13: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 14: Europe Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031

    Table 15: Asia Pacific Vaginitis Diagnostics Market (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 16: Asia Pacific Vaginitis Diagnostics Market (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 17: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 18: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031

    Table 19: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 20: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 21: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 22: Latin America Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2031

    Table 23: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2018–2031

    Table 24: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Testing Type, 2018–2031

    Table 25: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2018–2031

    Table 26: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2031

    List of Figures

    Figure 01: Global Vaginitis Diagnostics Market Snapshot

    Figure 02: Global Vaginitis Diagnostics Market Segments with Leading Market Share (%), 2021

    Figure 03: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast, 2022–2031

    Figure 04: Market Value Share (%), by Testing Type, 2021

    Figure 05: Market Value Share (%), by Disease Type, 2021

    Figure 06: Market Value Share (%), by End-user, 2021

    Figure 07: Market Value Share (%), by Region, 2021

    Figure 08: Global Vaginitis Diagnostics Market Value Share Analysis, by Testing Type, 2021 and 2031

    Figure 09: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nucleic Acid Amplification Assays, 2018–2031

    Figure 10: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by DNA Probe, 2018–2031

    Figure 11: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Clinical Test, 2018–2031

    Figure 12: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 13: Global Vaginitis Diagnostics Market Value Share Analysis, by Disease Type, 2021 and 2031

    Figure 14: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vulvovaginal Candidiasis, 2021-2031

    Figure 15: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bacterial Vaginosis/Vaginitis, 2021-2031

    Figure 16: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Trichomoniasis, 2021-2031

    Figure 17: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021-2031

    Figure 18: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 19: Global Vaginitis Diagnostics Market Value Share (%), by End-user, 2021 and 2031

    Figure 20: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2018–2031

    Figure 21: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialty Clinics, 2018–2031

    Figure 22: Global Vaginitis Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Others, 2018–2031

    Figure 23: Global Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 24: Global Vaginitis Diagnostics Market Value Share Analysis, by Region, 2021 and 2031

    Figure 25: Global Vaginitis Diagnostics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 26: North America Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 201–2031

    Figure 27: North America Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031

    Figure 28: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 29: North America Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031

    Figure 30: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 31: North America Vaginitis Diagnostics Market Value Share (%), by End-user, 2021 and 2031

    Figure 32: North America Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 33: North America Vaginitis Diagnostics Market Value Share (%), by Country, 2021 and 2031

    Figure 34: North America Vaginitis Diagnostics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 35: Europe Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031

    Figure 36: Europe Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031

    Figure 37: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 38: Europe Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031

    Figure 39: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 40: Europe Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031

    Figure 41: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 42: Europe Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 43: Europe Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 44: Asia Pacific Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031

    Figure 45: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031

    Figure 46: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 47: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031

    Figure 48: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 49: Asia Pacific Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031

    Figure 50: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 51: Asia Pacific Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 52: Asia Pacific Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 53: Latin America Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031

    Figure 54: Latin America Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031

    Figure 55: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 56: Latin America Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031

    Figure 57: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 58: Latin America Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031

    Figure 59: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 60: Latin America Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 61: Latin America Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 62: Middle East & Africa Vaginitis Diagnostics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2031

    Figure 63: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Testing Type, 2021 and 2031

    Figure 64: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Testing Type, 2022–2031

    Figure 65: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Disease Type, 2021 and 2031

    Figure 66: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Disease Type, 2022–2031

    Figure 67: Middle East & Africa Vaginitis Diagnostics Market Share (%), by End-user, 2021 and 2031

    Figure 68: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 69: Middle East & Africa Vaginitis Diagnostics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 70: Middle East & Africa Vaginitis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 71: Global Vaginitis Diagnostics Market Share Analysis, by Company (2021)

Copyright © Transparency Market Research, Inc. All Rights reserved